Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
Examination of Efficacy and Safety of SERM or Bisphosphonates After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
Shinshu University
90 participants
Nov 24, 2018
INTERVENTIONAL
Conditions
Summary
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy: SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months
Eligibility
Inclusion Criteria1
- osteoporosis patients
Exclusion Criteria1
- not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
To examine the effects of SERM and ELD in osteoporosis patients
To examine the effects of BP and ELD in osteoporosis patients
To examine the effects of ELD in osteoporosis patients
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03755193